Skip to main content
letter
. 2022 Jun 28;15:851–854. doi: 10.2147/JAA.S354013

Figure 1.

Figure 1

Adjusted annualized rate of severe asthma exacerbations in patients with and without clinically meaningful improvements in pre-bronchodilator FEV1 during the QUEST study (patients with uncontrolled, moderate-to-severe asthma and a type 2 phenotype) were analyzed using a negative binomial regression model. ***p < 0.001 vs placebo.

Abbreviations: BD, bronchodilator; CI, confidence interval; FEV1, forced expiratory volume in 1 second.